Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
02 August 2006Website:
http://www.anavex.comNext earnings report:
27 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:40:42 GMTDividend
Analysts recommendations
Institutional Ownership
AVXL Latest News
Data of Blarcamesine confirm upstream SIGMAR1 activation Presented as Late Breaking Oral Communications at Clinical Trials on Alzheimer's Disease (CTAD) Conference 2024 Oral, once daily blarcamesine meaningfully slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today presented new data from the Phase IIb/III study showing that blarcamesine (ANAVEX®2-73), once daily orally, demonstrates pre-specified clinical efficacy through upstream SIGMAR1 activation. Clinical data confirmed the mechanism of action (MoA) by pre-specified SIGMAR1 gene analysis in people with early Alzheimer's disease (AD).
Part A of the placebo-controlled Phase 2 study has been completed ANAVEX®3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG biomarkers of schizophrenia Patients are currently being dosed in Part B of the Phase 2 study which will investigate a longer treatment duration NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced encouraging preliminary electroencephalography (EEG) biomarker results from the Part A of the ongoing placebo-controlled Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia. Part A of the Phase 2 study ANAVEX®3-71-SZ-001 (NCT06245213), was a multiple ascending dose study in 16 participants treated with either oral placebo, oral ANAVEX®3-71 90 mg daily, or oral ANAVEX®3-71 180 mg daily for 10 days.
Company to host a webcast today at 8:30 a.m. Eastern Time
Webcast and Conference Call To be Held Tuesday, August 6, 2024, 8:30 am ET Webcast and Conference Call To be Held Tuesday, August 6, 2024, 8:30 am ET
Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference being held June 27, 2024.
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), indicating increased confidence in the company's earnings potential. This could lead to a rise in the stock price in the short run.
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference, April 8 – 11, 2024. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company scheduled at 8:45 AM (ET) on Monday, April 8th, 2024.
Anavex Life Sciences Corp. (AVXL) Q1 2024 Earnings Call Transcript
GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.
- 1(current)
- 2
What type of business is Anavex Life Sciences?
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
What sector is Anavex Life Sciences in?
Anavex Life Sciences is in the Healthcare sector
What industry is Anavex Life Sciences in?
Anavex Life Sciences is in the Biotechnology industry
What country is Anavex Life Sciences from?
Anavex Life Sciences is headquartered in United States
When did Anavex Life Sciences go public?
Anavex Life Sciences initial public offering (IPO) was on 02 August 2006
What is Anavex Life Sciences website?
https://www.anavex.com
Is Anavex Life Sciences in the S&P 500?
No, Anavex Life Sciences is not included in the S&P 500 index
Is Anavex Life Sciences in the NASDAQ 100?
No, Anavex Life Sciences is not included in the NASDAQ 100 index
Is Anavex Life Sciences in the Dow Jones?
No, Anavex Life Sciences is not included in the Dow Jones index
When was Anavex Life Sciences the previous earnings report?
No data
When does Anavex Life Sciences earnings report?
The next expected earnings date for Anavex Life Sciences is 27 November 2024